HIV-1 coreceptor use in triple-class treatment-experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response

Journal of Infectious Diseases

Volumn 194, Issue 2, 2006, Pages 238-246

  Melby, Tom ^a   DeSpirito, Michael ^a   DeMasi, Ralph ^a   Heilek Snyder, Gabrielle ^b   Greenberg, Michael L ^a   Graham, Neil ^a  

^a Trimeris Inc   (United States)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; ENFUVIRTIDE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; EXPERIENCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RECEPTOR BINDING; TARGET CELL; VIRUS ENVELOPE; VIRUS LOAD; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREVALENCE; RECEPTORS, HIV; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33746160257     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/504693     Document Type: Article

References (49)

1. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280:1884-8.
2. Sattentau QJ, Moore JP. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991; 174:407-15.
3. Doms RW, Moore JP. HIV-1 membrane fusion: targets of opportunity. J Cell Biol 2000; 151:F9-14.
4. Greenberg M, Cammack N, Salgo M, Smiley L. HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol 2004; 14:321-37.
5. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992; 66:1354-60.
6. Fenyo EM, Morfeldt-Manson L, Chiodi F, et al. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988; 62:4414-9.
7. + T cell decline. Proc Natl Acad Sci USA 2000; 97:1269-74.
8. + T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virol 1999; 73:6430-5.
9. Koot M, Keet IPM, Vos AHV, et al. Articles: prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-8.
10. Koot M, van Leeuwen R, de Goede REY, et al. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999; 179:254-8.
11. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185:621-8.
12. Brumme ZL, Dong WW, Yip B, et al. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. Aids 2004; 18:F1-9.
13. Delobel P, Sandres-Saune K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38:382-92.
14. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-74.
15. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866-72.
16. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005; 40:413-21.
17. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993; 9:1051-3.
18. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302-7.
19. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-95.
20. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40:404-12.
21. Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 1998; 95:15613-7.
22. Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine coreceptor usage in HIV. Curr Opin Infect Dis 2005; 18:9-15.
23. Greenberg M, Melby T, Sista P, et al. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 through 24 weeks [abstract 141]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003.
24. Melby T, DeMasi R, Kuritzkes D, Heilek-Snyder G, Salgo M, Greenberg M. Analyses of virological response and enfuvirtide resistance through 48 weeks in the TORO 1 and 2 studies [abstract 165]. In: Program and abstracts of the XIIIth International Drug Resistance Workshop (Tenerife Sur-Costa Adeje, Canary Islands, Spain). London: International Medical Press, 2004:S181.
25. Melby T, Sista P, Demasi R, et al. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfurvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. Aids Res Hum Retroviruses 2006; 22:375-85.
26. Demarest J, Bonny T, Vavro C, et al. HIV-1 co-receptor tropism in treatment naive and experienced subjects [abstract H-1136]. In: Program and abstracts of the 44th International Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
27. Lalezari J, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85.
28. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-95.
29. Sista P, Melby T, Greenberg M, et al. Subgroup analysis of baseline (BL) susceptibility and early virological response to enfuvirtide in the combined TORO studies [abstract 55]. In: Program and abstracts of the XIIth International HIV Drug Resistance Workshop (Los Cabos, Mexico). London: International Medical Press, 2003:S60.
30. Tersmette M, de Goede RE, Al BJ, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988; 62:2026-32.
31. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169:968-74.
32. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004; 20:111-26.
33. Bozzette SA, McCutchan JA, Spector SA, Wright B, Richman DD. A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J Infect Dis 1993; 168:1374-9.
34. Furrer H, Wendland T, Minder C, et al. Association of syncytium-inducing phenotype of HIV-1 with CD4 cell count, viral load and sociodemographic characteristics. AIDS 1998; 12:1341-6.
35. Karlsson I, Antonsson L, Shi Y, et al. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol 2004; 78:11807-15.
36. Trkola A, Kuster H, Leemann C, et al. Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection. J Virol 2003; 77:13146-55.
37. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127:882-90.
38. Ostrowski MA, Justement SJ, Catanzaro A, et al. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 1998; 161:3195-3201.
39. Sheppard HW, Celum C, Michael NL, et al. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr 2002; 29:307-13.
40. Su C, DeMasi R, Heilek-Snyder G, et al. Early additional CD4+ T cell count gains independent of viral suppression in the setting of enfuvirtide (T20) treatment. In: Program and abstracts of Frontiers in Drug Development for Antiretroviral Therapies (Montego Bay, Jamaica). Tucker, GA: Informed Horizons, 2004.
41. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001; 75: 8605-14.
42. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002; 99:16249-54.
43. Philpott S, Weiser B, Anastos K, et al. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 2001; 107:431-8.
44. Skrabal K, Trouplin V, Labrosse B, et al. Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS 2003; 17:809-14.
45. Ribeiro RM, Hazenberg MD, Perelson AS, Davenport MP. Naive and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J Virol 2006; 80:802-9.
46. Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000; 25:99-102.
47. Tremblay CL, Giguel F, Kollmann C, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002; 46:1336-9.
48. Vermeire K, Princen K, Hatse S, et al. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS 2004; 18:2115-25.
49. Nagashima KA, Thompson DAD, Rosenfield SI, Maddon PJ, Dragic T, Olson WC. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001; 183:1121-5.